Success Metrics

Clinical Success Rate
63.6%

Based on 7 completed trials

Completion Rate
64%(7/11)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
4(36%)

Phase Distribution

Ph phase_2
6
55%
Ph phase_3
5
45%

Phase Distribution

0

Early Stage

6

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
6(54.5%)
Phase 3Large-scale testing
5(45.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

63.6%

7 of 11 finished

Non-Completion Rate

36.4%

4 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(7)
Terminated(4)

Detailed Status

Completed7
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
63.6%
Most Advanced
Phase 3

Trials by Phase

Phase 26 (54.5%)
Phase 35 (45.5%)

Trials by Status

completed764%
terminated436%

Recent Activity

0 active trials
Showing 5 of 11
terminatedphase_2

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

NCT00788541
terminatedphase_3

Anecortave Acetate Risk Reduction Trial (AART)

NCT00332657
completedphase_2

Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

NCT00315640
terminatedphase_3

Anecortave Acetate Risk-Reduction Trial (AART)

NCT00333216
completedphase_3

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

NCT00299507
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT00788541Phase 2

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

Terminated
NCT00332657Phase 3

Anecortave Acetate Risk Reduction Trial (AART)

Terminated
NCT00315640Phase 2

Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

Completed
NCT00333216Phase 3

Anecortave Acetate Risk-Reduction Trial (AART)

Terminated
NCT00299507Phase 3

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

Completed
NCT00307398Phase 3

Anecortave Acetate Risk-Reduction Trial (AART)

Terminated
NCT00320203Phase 2

Anecortave Acetate in Patients With Open-angle Glaucoma

Completed
NCT00691717Phase 2

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed
NCT00451152Phase 2

Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

Completed
NCT00051129Phase 3

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

Completed
NCT00346957Phase 2

A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

Completed

All 11 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
11